Concorde Clinical Trials

Concorde Medical Group’s Clinical Trials Program is actively recruiting patients for several research trials. Patients who participate in these trials assist in the advancement of medical science, gain access to cutting-edge treatments, may be eligible to receive medications at no cost, and may receive monetary reimbursement for participation.

Ulcerative Colitis:

This is a 12-month study, sponsored by Procter and Gamble, comparing the efficacy of Asacol once a day versus the same dose of Asacol twice a day. The study requires 5 to 6 office visits over the course of one year. To be eligible, patient must have had one colitis flare over the last 18 months.

Hepatitis B

Two hepatitis B treatment trials, sponsored by Bristol Myers Squibb, are actively enrolling patients. The first study compares the relative efficacy of Entecavir alone versus the combination of Entecavir and tenofovir in patients who have not been previously treated for hepatitis B. The second study compares three medication regimens:  Entecavir alone versus Adefovir plus Lamivudine versus Entecavir plus Adefovir in patients who did not respond to Lamivudine alone. 

Hepatitis C

This is an observational study sponsored by Roche for patients getting ready to start treatment for Hepatitis C who have not been previously treated. In this study, patients would receive their usual care for the treatment of Hepatitis C.

IRRITABLE BOWEL SYNDROME (IBS)

Because the cause of IBS is unknown, new and better IBS treatments are currently being researched to improve the quality of life for those who suffer from IBS. Our doctors are now conducting a clinical research study evaluating the effectiveness of an investigational medication for the treatment of IBS.

We encourage you to inquire about the study if you have:

• Abdominal discomfort, bloating and other symptoms associated with IBS
• Loose, frequent, and/or watery stool.

Qualified participants will receive study medication and study-related medical evaluations at no cost. Reimbursement for study participation will be provided.

If you are interested in learning more about any one of these clinical research trials, please contact study coordinator Maureen Haskins at 212-889-5544 ext 152 or
e-mail at .

In This Section